Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 11, 2022

SELL
$1.3 - $3.17 $218,605 - $533,060
-168,158 Closed
0 $0
Q3 2021

Nov 04, 2021

SELL
$2.91 - $4.5 $261,341 - $404,136
-89,808 Reduced 34.81%
168,158 $504,000
Q2 2021

Aug 11, 2021

BUY
$4.15 - $6.3 $958,774 - $1.46 Million
231,030 Added 857.7%
257,966 $1.2 Million
Q1 2021

May 13, 2021

BUY
$5.51 - $9.42 $2,457 - $4,201
446 Added 1.68%
26,936 $161,000
Q4 2020

Feb 16, 2021

BUY
$3.42 - $6.36 $27,578 - $51,287
8,064 Added 43.76%
26,490 $139,000
Q3 2020

Nov 12, 2020

BUY
$2.94 - $12.43 $832 - $3,517
283 Added 1.56%
18,426 $64,000
Q2 2020

Aug 13, 2020

BUY
$5.28 - $9.67 $45,276 - $82,920
8,575 Added 89.62%
18,143 $157,000
Q1 2020

May 14, 2020

SELL
$5.0 - $7.6 $2,880 - $4,377
-576 Reduced 5.68%
9,568 $55,000
Q4 2019

Feb 14, 2020

BUY
$5.99 - $8.38 $17,125 - $23,958
2,859 Added 39.25%
10,144 $73,000
Q3 2019

Nov 14, 2019

SELL
$5.62 - $9.63 $4,372 - $7,492
-778 Reduced 9.65%
7,285 $43,000
Q2 2019

Aug 14, 2019

SELL
$7.59 - $10.21 $159,678 - $214,797
-21,038 Reduced 72.29%
8,063 $75,000
Q1 2019

May 15, 2019

BUY
$7.65 - $16.66 $4,000 - $8,713
523 Added 1.83%
29,101 $234,000
Q4 2018

Feb 14, 2019

BUY
$10.76 - $17.25 $184,555 - $295,872
17,152 Added 150.11%
28,578 $464,000
Q3 2018

Dec 21, 2021

BUY
$14.34 - $22.97 $19,014 - $30,458
1,326 Added 13.13%
11,426 $186,000
Q3 2018

Nov 14, 2018

BUY
$14.34 - $22.97 $6,037 - $9,670
421 Added 4.35%
10,100 $164,000
Q2 2018

Apr 21, 2020

BUY
$12.76 - $16.94 $20,900 - $27,747
1,638 Added 20.37%
9,679 $145,000
Q2 2018

Aug 14, 2018

BUY
$12.76 - $16.94 $102,603 - $136,214
8,041 New
8,041 $120,000

Others Institutions Holding UBX

# of Institutions
1
Shares Held
4.41M
Call Options Held
0
Put Options Held
0

About Unity Biotechnology, Inc.


  • Ticker UBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,036,200
  • Market Cap $16.1M
  • Description
  • Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...
More about UBX
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.